Certified by Founder
Lodge
AlgoTx
start up
France
- Suresnes, Ile-de-France
- 15/03/2023
- Series B
- $21,157,000
AlgoTx develops novel solutions for complex pain. Our lead program, ATX01, targets highly prevalent Chemotherapy-Induced Peripheral Neuropathy and the orphan disease erythromelalgia.
- Industry Biotechnology Research
- Website https://www.linkedin.com/company/algotx/about/
- LinkedIn https://www.linkedin.com/company/algotx/
Valinor | $13,000,000 | (Dec 12, 2025)
Keeper | $4,000,000 | (Dec 12, 2025)
Cyphlens | $3,800,000 | (Dec 12, 2025)
OnCorps AI | $55,000,000 | (Dec 12, 2025)
conveyd | $3,345,837 | (Dec 12, 2025)
Ritten | $35,000,000 | (Dec 12, 2025)
Safebooks AI | $15,000,000 | (Dec 12, 2025)
Double (1) | $6,500,000 | (Dec 12, 2025)
Yonda | $15,000,000 | (Dec 12, 2025)
Medra | $52,000,000 | (Dec 12, 2025)
Cynch AI | $9,000,000 | (Dec 12, 2025)
Empromptu.ai | $2,000,000 | (Dec 11, 2025)